The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
Subscribe To Our Newsletter & Stay Updated
